New data on lecanemab to be presented at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and associate Eisai in the present day ...
Tag: Lecanemab
Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer’s Disease Under The Accelerated Approval Pathway
TOKYO and CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Eisai Company, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ...
POPULAR NEWS
EDITOR'S PICK
